Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ

Area of Science:

• Biomedical Engineering
• Cancer Biology
• Regenerative Medicine

Background:

• Effective delivery of apoptosis-inducing agents like tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to tumors is a significant challenge in cancer therapy.
• Mesenchymal stem cells (MSCs) possess inherent tumor-homing capabilities and can be engineered to express therapeutic genes, offering a potential platform for targeted drug delivery.

Purpose of the Study:

• To develop and evaluate a scaffold-based delivery system for sustained release of TRAIL-expressing MSCs (FLT-MSCs) for cancer treatment.
• To assess the efficacy of this system in inhibiting tumor growth and metastasis in preclinical models.

Main Methods:

• Porous silk scaffolds were fabricated and seeded with full-length TRAIL-expressing MSCs (FLT-MSCs) under a doxycycline-inducible promoter.
• In vitro studies confirmed TRAIL expression and antitumor effects of FLT-MSCs on breast cancer cells.
• FLT-MSCs were administered to mice via mammary fat pad co-injection, tail vein injection, or subcutaneous scaffold implantation.

Main Results:

• In vitro studies showed FLT-MSC inhibition of breast cancer cell growth.
• Scaffold-based delivery and other routes reduced bone and lung metastasis; liver metastasis reduction varied by administration route.
• Doxycycline-induced TRAIL expression in co-injection and scaffold groups significantly decreased average tumor burden compared to controls.

Conclusions:

• The scaffold-based therapeutic delivery system represents a novel and effective approach for anticancer therapy.
• This system demonstrates significant potential for future clinical applications in cancer treatment.